NPM1c-specific TCR T-cell therapy

NPM1c-specific TCR T-cell therapy is an investigational adoptive cellular immunotherapy targeting the cytoplasmic mutant form of nucleophosmin 1 (NPM1c), a frequent driver mutation in acute myeloid leukemia (AML). The therapy utilizes autologous T cells genetically engineered to express a T-cell receptor (TCR) specific for NPM1c-derived neoantigens, such as the AIQDLCLAV or CLAVEEVSL peptides, presented by the HLA-A*02 MHC class I molecule. This approach allows for the selective recognition and destruction of leukemia blasts while minimizing off-target toxicity to healthy hematopoietic stem cells, which do not express the mutant protein. Clinical development is currently focused on treating patients with relapsed or refractory NPM1-mutated AML, with scalable automated production platforms being developed to support clinical application.

Other names

NPM1c-targeted TCR-T therapyNPM-1c-targeted TCR-T therapyNPM 1c-targeted TCR-T therapyNPM1c-specific TCR-engineered T-cell therapyNPM-1c-specific TCR-engineered T-cell therapyNPM 1c-specific TCR-engineered T-cell therapyNPM1c-specific TCR T-cell therapyNPM-1c-specific TCR T-cell therapyNPM 1c-specific TCR T-cell therapy